slot meter

Daix (France), New York City, (New York, United States), November 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH”), also known as non-alcoholic steatohepatitis ("NASH”), and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2024 and its revenues for the first nine months of 2024. Cash and cash equivalents As of September 30, 2024, the Company's cash and cash equivalents amounted to €13.9 million, compared to cash and cash equivalents at €26.9 million, short-term deposit 4 at €0.01 million, and long-term deposit 5 at €9.0 million as of December 31, 2023. Net cash used in operating activities amounted to (€64.2) million in the first nine months of 2024, compared to (€69.0) million for the same period in 2023 down by 7.0%. R&D expenses, mainly driven by the development of lanifibranor in MASH/NASH, for the first nine months of 2024 amounted to €71.7 million and were down 10.0% compared to the €79.6 million for the first nine months of 2023. The decrease in R&D expenses over the period is primarily due to the temporary voluntary pause in the recruitment of patients in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH/NASH ("NATiV3") following the Suspected Unexpected Serious Adverse Reaction ("SUSAR”) previously reported in the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND Phase 2a combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes ("T2D”). R&D expenses have started to increase as expected in the second half of 2024 following the restart of patient recruitment in NATiV3, as well as the planned clinical development activities and related costs associated with the NATiV3 for the second half of 2024. Net cash generated from investing activities for the first nine months of 2024 amounted to €8.7 million, compared to (€3.5) million used for the same period in 2023. The change is mostly due to the variation in term deposits between both periods. Net cash generated from financing activities for the first nine months of 2024 amounted to €42.3 million compared to €30.2 million in the same period in 2023. The change is due to (i) the second tranche of €25 million drawn in January 2024 under the unsecured loan agreement granted by the European Investment Bank ("EIB”) with the issue of 3,144,654 warrants to the EIB, and (ii) the issuance on July 18, 2024, of royalty certificates (the "2024 Royalty Certificates”) subscribed by Samsara BioCapital, and existing shareholders BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of €20.1 million. The 2024 Royalty Certificates give the holders thereof the right to an annual payment of royalties equal to 3% of the potential future net sales of lanifibranor, if any, in the United States, the European Union and the United Kingdom over a 14-year term from the date of their issuance 6 . Over the first nine months of 2024, the Company did not record any exchange rate effect on cash and cash equivalents, compared to a negative exchange rate effect of (€0.7) million for the same period in 2023, due to the evolution of the EUR/USD exchange rate. Financial information after closing the accounts On October 14, 2024, the Company announced a multi-tranche equity financing (the "Equity Raise”) of up to €348 million from both new and existing investors 2 . The Company closed the first part of the first tranche of the Equity Raise on October 17, 2024, and issued 34,600,507 new ordinary shares (the "T1 New Shares”) at a price of €1.35 per T1 New Share, and 35,399,481 prefunded warrants to purchase ordinary shares in the Company at an exercise price of €0.01 and a subscription price of €1.34 per new ordinary share and received €94.1 million in gross proceeds (net proceeds approximately €86.6 million). The second part of the first tranche and the second and third tranches of the Equity Raise remain subject to satisfaction of specified conditions, and in particular shareholder approval. On October 14, 2024, the Company also announced that it had amended its license and collaboration agreement with Chia Tai Tianqing Pharmaceutical (Guangzhou) CO., LTD. ("CTTQ”). Pursuant to the amendment, if the Company receives commitments from investors to subscribe to an equity raise, in two or three tranches, prior to December 31, 2024, for an aggregate amount of at least €180 million, CTTQ shall pay to the Company (i) $10 million within 30 days of settlement-delivery of the new shares and prefunded warrants in the first tranche of the Equity Raise, (ii) $10 million upon the completion of the second tranche of the Equity Raise and (iii) $10 million upon the publication by the Company of positive topline data announcing that any key primary endpoint or key secondary endpoint of the NATiV3 trial, with any dosage regimen tested in the trial, have been met. Under the terms of the Amendment, the total amount of milestone payments remains unchanged, while the royalties that Inventiva is eligible to receive have been reduced to the low single digits. The signing of the Equity Raise satisfied the condition of receiving commitments for an aggregate amount of at least €180 million and the closing of the first part of the first tranche of the Equity Raise satisfied the condition (i) above. Subsequently, on November 18, 2024, the Company received the first milestone payment of $10 million from CTTQ pursuant to this amendment. Considering its current cost structure and forecasted expenditures and including (i) the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the Equity Raise, and (ii) the first milestone of $10 million (gross proceeds) received under the amendment to the licensing agreement with CTTQ, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 2025 2 . The Company currently expects that the conditions for the closing of the second part of the first tranche of the Equity Raise will be satisfied in December 2024. Considering its current cost structure and forecasted expenditures, the Company estimates that the anticipated receipt of the proceeds (a gross amount of €21.4 million) from the second part of the first tranche of the Equity Raise announced on October 14, 2024 would be sufficient to extend the Company's ability to finance its operations until middle of the third quarter of 2025. Revenues The Company's revenues for the first nine months of 2024 amounted to €1.3 million, as compared to €1.9 million for the same period in 2023. *** Next key milestones expected Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate and has a pipeline of two preclinical programs. Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase 3 clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease. Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program. The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Pascaline Clerc EVP, Strategy and Corporate Affairs [email protected] +1 202 499 8937 Tristan Roquet Montegon Aude Lepreux Julia Cailleteau Media relations [email protected] +33 1 53 96 83 83 Patricia L. Bank Investor relations [email protected] +1 415 513 1284 Important Notice This press release contains "forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, unaudited financial information, forecasts and estimates with respect to Inventiva's cash resources, the anticipated proceeds from the Equity Raise, completion and timing of the Equity Raise, the satisfaction in part or full of the conditions precedent to closing of the various tranches of the Equity Raise and the timing thereof, and the exercise by the investors of the warrants and pre-funded warrants issued in connection with the Equity Raise, Inventiva's expectations regarding its collaboration agreement with CTTQ, including the achievement of specified milestones thereunder, forecasts and estimates with respect to Inventiva's pre-clinical programs and clinical trials, including design, protocol, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase 3 clinical trial with lanifibranor in MASH/NASH, the clinical development of and regulatory plans and pathway for lanifibranor, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva's product candidates, including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva's pipeline and preclinical and clinical development plans, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, and business and regulatory strategy, the potential commercialization of lanifibranor and achievement of any sales related thereto, potential payment of royalties and anticipated future performance. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes”, "anticipates”, "expects”, "intends”, "plans”, "seeks”, "estimates”, "may”, "will”, "would”, "could”, "might”, "should”, "designed”, "hopefully”, "target”, "potential”, "opportunity”, "possible”, "aim”, and "continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's ability to obtain financing and to enter into potential transactions and Inventiva's ability to satisfy in part or full the conditions precedent for additional tranches of the Equity Raise and the conditions with respect to CTTQ, and whether and to what extent the Warrants may be exercised and by which holders, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva's and its partners' clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2023 filed with the Autorité des Marchés Financiers on April 3, 2024, as amended on October 14, 2024, the Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC”) on April 3, 2024, and the Half-Year Report for the six months ended June 30, 2024 on Form 6-K filed with the SEC on October 15, 2024 for other risks and uncertainties affecting Inventiva, including those described under the caption "Risk Factors”, and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. 1 Non-audited financial information. 2 Press release of October 14, 2024 3 This estimate is based on the Company's current business plan and excludes any potential milestones payable to or by the Company and any additional expenditures related to the potential continued development of the odiparcil program or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. 4 Short-term deposits were included in the category "other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available. 5 The long-term deposit had a two year-term, was accessible prior to the expiration of the term with a notice period of 31 days and was considered as liquid by the Company. 6 Press release of July 18, 2024 Attachment Inventiva - PR - Q3 2024 CA Cash - EN - 11 21 2024 - FinalThe 11 Best Sweatshirts You’ll Want to Wear All Dayslot meter 。

Food delivery firm, Zomato, is set to make its entry in the key equity benchmark index, BSE Sensex. The company will replace JSW Steel to secure a spot in the Sensex as part of the index reconstitution. The development becomes effective from December 23, 2024. Asia Index Private Ltd, the wholly-owned subsidiary of BSE announced the reconstitution on Friday of several indices such as BSE Sensex Next 50, BSE 100, and BSE Sensex 50, reported The Economic Times. The food delivery and quick commerce firm will enter the 30-stock benchmark index after delivering a solid rally over the last year. The company’s shares surged ahead in the last one year and yielded 130 per cent returns for the investors in the concerned period. Meanwhile, Sensex itself couldn’t manage to deliver the same performance. The index’s yield over 12-months stood at 20 per cent. On the other hand, JSW Steel delivered returns of 27 per cent in the 12-month period. Also Read : SEBI Issues Governance Guidelines, Asks MIIs To Resolve Whistleblower Complaints In 60 Days Meanwhile, six stocks were added to the BSE 100 index. These included Suzlon Energy, Adani Green Energy, Jio Financial Services, Samvardhana Motherson International, PB Fintech (Policybazaar), and Adani Power. These stocks will be added to the list after replacing P I Industries, IDFC First Bank, Ashok Leyland, APL Apollo Tubes, UPL, and Indian Railway Catering and Tourism Corporation (IRCTC). As part of reconstitution in the BSE Sensex 50 index, Zomato, PSU Hindustan Aeronautics (HAL), and Jio Financial Services will be added to the index. The stocks making their exit from the index include Bharat Petroleum Corporation (BPCL), LTIMindtree, and HDFC Life Insurance Company. In the last trading session on Friday, both Sensex and Nifty made a strong recovery and climbed more than 2 per cent each. The BSE Sensex surged 1,961 points and closed the session at 79,117, while the NSE Nifty50 rallied more than 550 points and ended trading at 23,907. Also Read : Company Imposes Strict Leave Policy, Bars Employees From Taking Sick Days During Holiday Season. Check Viral Post

None

Pitt quarterback Eli Holstein leaves game with left leg injury against Louisville

If you are into horror games and still haven't played Silent Hill 2, now is a great chance to start as the PS5 version of Silent Hill 2 is more than half off at Walmart for Black Friday . As one of several Black Friday video game deals going on right now, the Silent Hill 2 remake was one highly requested by fans, and it did not disappoint. The game makes you uncomfortable but in an effective and thrilling way. In true horror fashion, there's blackout darkness, suffocating fog, unknown noises, grotesque enemies, and isolation. From our review, Matt Purslow states "The remake is a modern reminder not just of an era where Konami was a master of survival horror, but also the significant power of Silent Hill 2’s unrelenting misery." So, are you ready to play one of the best horror games of all time? Get Silent Hill 2 for $30 ( $69 ) More PlayStation Black Friday Deals We've Found On the video game front, we found Final Fantasy VII Rebirth (which is fantastic) is at its lowest price ever. Alternatively, if you prefer FromSoftware, Elden Ring is also on sale which gives you an easy way to enjoy this year’s Game of the Year-nominated Shadow Of the Erdtree DLC (which is also discounted right now . If you want to convince a friend to grab a PlayStation 5 to play with you, or you're the greatest gift-giver of all time, you can spread the word or grab this deal on a PS5 now . If you’ve been looking to try out VR, the PSVR2 Horizon: Call of the Mountain bundle is $250 off . For more PlayStation deals, check out our hub for the best PlayStation Black Friday deals . Top 10 Walmart Black Friday Deals When Is Black Friday 2024? We’re in the home stretch: Black Friday falls on November 29 this year. All month long, retailers have been rolling out sales, ramping up to massive discounts on Black Friday and through the weekend into Cyber Monday. As mentioned above, there are already fantastic deals on PS5 consoles (including PSVR2 ), PS5 controllers , and tons more. Brian Barnett writes reviews, guides, features, & more for IGN, GameSpot, & Kotaku. You can get more than your fair share of him on Bluesky & Backloggd , & enjoy his absurd video game talk show, The Platformers, on Spotify & Apple Podcasts .None

Target Shares Plunge on Its Holiday Outlook. Should Investors Buy the Dip in the Stock?

ISLAMABAD, (UrduPoint / Pakistan Point News - 23rd Nov, 2024) Parliamentary Secretary for Information and Broadcasting Danyal Chaudhry said that the would not allow any mob to on and damage the economic growth of the country and create hurdles for the citizens. Addressing at a press conference here on Saturday, he said that due to the conducive policies of the incumbent regime after a long time again country's economy is on track and the growth ratio increasing day by day but unfortunately some elements wanted to disrupt it. The nation knew that these people were not sincere with the development and prosperity of the state. Danyal also condemned the statement of regarding and blamed the wanted to damaging the current strong and bilateral relationships. He said that had signed a number of MoUs with regimes recently and trade volume would be enhanced very soon, but some elements wanted to sabotage the journey of . He criticized that the founder of had sold the gifts of brother country adding that is the and most trustworthy friend of . He said that the graph of inflation decreased double digits to single and the growth of economics on smooth way and ratio of interest also reduced. Overseas Pakistanis fully support the incumbent as 3.1 were sent by expatiate in the first week of 2024. Danyal underlined that announced a good relief to the citizens in billing. Stock going up due to the local and foreign investment in the country, he added.Logistical issues meant that thousands of Namibians were still waiting to vote in pivotal presidential and legislative elections late on Wednesday as the polling stations were scheduled to close. The vote could usher in the desert nation's first woman leader even as her party, the ruling South West Africa People's Organisation (SWAPO) faces the strongest challenge yet to its 34-year grip on power. Some voters told AFP they queued all day, for up to 12 hours, blaming technical problems which included issues with voter identification tablets or insufficient ballot papers. According to Namibia's electoral law, those in the queue before the polls closed -- scheduled at 9:00 pm (1900 GMT) -- should be allowed to vote. "We have the obligation to make sure that they pass their vote," said Petrus Shaama, chief officer of the Electoral Commission of Namibia (ECN). The main opposition party, the Independent Patriots for Change (IPC) has blamed the ECN for the long lines and cried foul play. "We have reason to believe that the ECN is deliberately suppressing voters and deliberately trying to frustrate voters from casting their vote," said Christine Aochamus of the IPC. She said the party had "started the process" of approaching a court "to order the ECN to extend the voting time". At one polling station inside Namibia's University of Science and Technology in the capital Windhoek, hundreds of people were still in line at 09:00 pm despite some having arrived at 6:00 am, an hour before polls opened. It was a similar situation at the Museum of Independence, according to an AFP reporter, where one voter said he arrived 12 hours earlier and was still in line with hundreds of others. SWAPO's candidate and current vice president, Netumbo Nandi-Ndaitwah, was one of the first to vote and called on Namibians "to come out in their numbers". An estimated 1.5 million people in the sparsely populated nation had registered to cast their ballot. SWAPO has governed since leading mineral-rich Namibia to independence from South Africa in 1990 but complaints about unemployment and enduring inequalities could force Nandi-Ndaitwah into an unprecedented second round. Leader of the IPC, Panduleni Itula, a former dentist and lawyer said he was optimistic he could "unseat the revolutionary movement". "We will all march from there and to a new dawn and a new era of how we conduct our public affairs in this country," the 67-year-old told reporters after voting. Itula took 29 percent of votes in the 2019 elections, losing to SWAPO leader Hage Geingob with 56 percent. It was a remarkable performance considering Geingob, who died in February, had won almost 87 percent five years before that. Namibia is a major uranium and diamond exporter but not many of its nearly three million people have benefitted from that wealth. "There's a lot of mining activity that goes on in the country, but it doesn't really translate into improved infrastructure, job opportunities," said independent political analyst Marisa Lourenco, based in Johannesburg. "That's where a lot of the frustration is coming from, (especially) the youth," she said. Unemployment among 15- to 34-year-olds is estimated at 46 percent, according to the latest figures from 2018, almost triple the national average. For the first time in Namibia's recent history, analysts say a second round is a somewhat realistic option. That would take place within 60 days of the announcement of the first round of results due by Saturday. "The outcome will be tight," said self-employed Hendry Amupanda, 32, who queued since 9:00 pm the night before to cast his ballot. "I want the country to get better and people to get jobs," said Amupanda, wearing slippers and equipped with a chair, blanket and snacks. Marvyn Pescha, a self-employed consultant, said his father was part of SWAPO's liberation struggle and he was not going to abandon the party. "But I want SWAPO to be challenged for better policies. Some opportunistic leaders have tarnished the reputation of the party, they misuse it for self-enrichment," the 50-year-old said. While lauded for leading Namibia to independence, SWAPO is nervous about its standing after other liberation-era movements in the region have lost favour with young voters. In the past six months, South Africa's African National Congress lost its parliamentary majority and the Botswana Democratic Party was ousted after almost six decades in power. clv/br/lhd/sbk

Trump selects longtime adviser Keith Kellogg as special envoy for Ukraine and RussiaRunner's World: Top RBs take flight when Ravens entertain Eagles

Saquon Barkley and the Philadelphia Eagles make their second-to-last road trip of the regular season Sunday to face Derrick Henry and the Baltimore Ravens. The NFC East-leading Eagles (9-2) have won seven in a row and play four of their final six games in Philadelphia, traveling only about 125 miles to visit the Ravens (8-4) this weekend and the Washington Commanders in Week 16. Sunday's game features the NFL's two leading rushers. Barkley (1,392 yards) and Henry (1,325) are far ahead of Green Bay's Josh Jacobs (944) in third place. Henry leads the league with 13 rushing touchdowns. Barkley (10) is tied for fourth and Philadelphia quarterback Jalen Hurts (11) tied for second. The matchup also features two of the top candidates for Most Valuable Player honors entering Week 13 in Barkley and Baltimore quarterback Lamar Jackson, who won his second MVP award last season. Their competition includes quarterbacks Josh Allen of Buffalo and Jared Goff of Detroit, with Allen widely considered the favorite. "Lamar Jackson and Derrick Henry are phenomenal football players that help their team win football games, and Jalen Hurts and Saquon Barkley are phenomenal football players that help their team win football games," Eagles coach Nick Sirianni said. "Excited about the opportunity this week because it's our next one. It will be a really good opponent, really well coached, good players, good atmosphere that will be there. Excited about the opportunity this week. And we're going to have to be on it against a really good team." The showdown at M&T Bank Stadium also pits Baltimore's No. 1 offense (426.7 yards per game) and No. 2 scoring offense (30.3 points per game) against Philadelphia's No. 1 defense (274.6) and No. 6 scoring defense (18.1). The Eagles have held seven consecutive opponents to under 300 total yards, while the Ravens have gained at least 329 yards of offense in all 11 games. Philadelphia is coming off a 37-20 road win over the Los Angeles Rams on Sunday night in which Barkley smashed the franchise record with 255 rushing yards. Baltimore also earned a prime-time win in Los Angeles, defeating the Chargers 30-23 in the "Harbaugh Bowl" on Monday night behind Jackson's three touchdowns (two passing, one rushing). Jackson said he's looking forward to the Barkley and Henry show. "I've known Saquon from high school. We were in the all-star game together and he jumped over somebody's head," Jackson recalled Wednesday. "So I've pretty much seen him before I even got to the league, college, anything. I've been knowing about Saquon, but Derrick Henry -- King Henry -- I'm with him every day and I'm seeing what he's capable of, so it's going to be a great matchup." Ravens linebacker Roquan Smith practiced Wednesday after sitting out Monday with a hamstring issue. Nose tackle Michael Pierce (calf) was designated to return from injured reserve. Tight end Charlie Kolar (broken arm) is out for several weeks and cornerback Arthur Maulet (calf) did not practice. The Eagles lost veteran defensive end Brandon Graham to a season-ending triceps injury Sunday. Wideout DeVonta Smith (hamstring) missed the win over the Rams and did not practice Wednesday. Neither did cornerbacks Darius Slay (concussion) or Kelee Ringo (calf). Philadelphia is 5-1 away from home this season -- 6-1 if you count their season-opening "home" victory against the Packers in Sao Paulo, Brazil. Baltimore is 4-1 at home. The Ravens hold a 3-2-1 lead in the series with the Eagles. They haven't met since Baltimore's 30-28 win in Week 6 at Philadelphia in 2020. --Field Level Media